EphA4‐deleted microenvironment regulates cancer development and leukemoid reaction of the isografted 4T1 murine breast cancer via reduction of an IGF 1 signal
Open Access
- 29 February 2016
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 5 (6), 1214-1227
- https://doi.org/10.1002/cam4.670
Abstract
EphA4 belongs to the largest family of receptor tyrosine kinases (RTKs). Although EphA4 is highly expressed in the central nervous system, EphA4 has also been implicated in cancer progression. Most of the studies focus on the expression and function in tumor cells. It is unknown whether EphA4‐deleted microenvironment affects tumor progression. Some of cancers in animals and humans, such as 4T1 cancer cells, are known to produce a large amount of granulocyte colony‐stimulating factors (G‐CSF/Csf3) which can stimulate myeloproliferation, such as myeloid‐derived suppressor cells (MDSCs) leading to a poor recipient prognosis. We isografted 4T1 breast cancer cells into both EphA4‐knockout and control wild‐type female littermate mice. The results showed that the EphA4‐deleted host could inhibit primary tumor growth and tumor metastasis mainly by decreasing the amount of IGF1 synthesis in the circulation and locally tissues. The EphA4‐deleted microenvironment and delayed tumor development reduced the production of G‐CSF resulting in the decrease of splenomegaly and leukemoid reaction including MDSCs, which in turn inhibit the tumor progression. This inhibition can be reversed by supplying the mice with IGF1. However, an excess of IGF1 supply over demand to the control mice could not further accelerate the tumor growth and metastasis. A better understanding and re‐evaluation of the main role of IGF1 in regulating tumor progression could further enhance our cognition of the tumor development niche. Our findings demonstrated that EphA4‐deleted microenvironment impairs tumor‐supporting conditions. Conclusion: Host EphA4 expression regulates cancer development mainly via EphA4‐mediated IGF1 synthesis signal. Thus, targeting this signaling pathway may provide a potential therapeutic option for cancer treatment.Keywords
Funding Information
- Wakayama Medical University
This publication has 50 references indexed in Scilit:
- The Insulin-Like Growth Factor System in CancerEndocrinology and Metabolism Clinics of North America, 2012
- Protein dynamics and conformational selection in bidirectional signal transductionBMC Biology, 2012
- Tumor-Derived G-CSF Facilitates Neoplastic Growth through a Granulocytic Myeloid-Derived Suppressor Cell-Dependent MechanismPLOS ONE, 2011
- Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in HumansScience Translational Medicine, 2011
- Cancer-Associated Myeloproliferation: Old Association, New Therapeutic TargetMayo Clinic Proceedings, 2010
- Eph receptors and ephrins in cancer: bidirectional signalling and beyondNature Reviews Cancer, 2010
- Eph Receptors and Ephrins in Cancer: Common Themes and ControversiesCancer Research, 2008
- Eph/ephrin signaling in epithelial development and homeostasisThe International Journal of Biochemistry & Cell Biology, 2008
- Targeted Deletion of Hepatic Igf1 in TRAMP Mice Leads to Dramatic Alterations in the Circulating Insulin-Like Growth Factor Axis but Does Not Reduce Tumor ProgressionCancer Research, 2008
- Mechanisms and functions of eph and ephrin signallingNature Reviews Molecular Cell Biology, 2002